Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with ...

FDA expands approval for setmelanotide to patients with hypothalamic obesity

The FDA has approved an expanded indication for setmelanotide to treat children and adults with acquired hypothalamic obesity, Rhythm Pharmaceuticals announced. Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is a melanocortin-4 receptor agonist that was previously approved by the FDA to treat children and adults with obesity due to Bardet-Biedl syndrome, genetically confirmed

After setback, Rhythm gets good news on Imcivree from FDA

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

Rhythm obesity drug wins broader use from FDA

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with ...

- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction –

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight...

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - Rhythm Pharmaceuticals (NASDAQ:RYTM)

- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction –  -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by s…